Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio E. Bertorini, Robert Bowser, Mark B. Bromberg, Andrew Brown, O. Carbunar, Gregory T. Carter, J. Crayle, Keelie Denson, Eva Feldman, Timothy R Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascías Cadavid, C. Mcdermott, Tasnim Mushannen, L. Ostrow, Ronak Patel, Gary L. Pattee, Dylan Ratner, Yuyao Sun, J. Sladky, Paul Wicks, Richard Bedlack
{"title":"ALSUntangled #75:便携式神经调控刺激器疗法","authors":"Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio E. Bertorini, Robert Bowser, Mark B. Bromberg, Andrew Brown, O. Carbunar, Gregory T. Carter, J. Crayle, Keelie Denson, Eva Feldman, Timothy R Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascías Cadavid, C. Mcdermott, Tasnim Mushannen, L. Ostrow, Ronak Patel, Gary L. Pattee, Dylan Ratner, Yuyao Sun, J. Sladky, Paul Wicks, Richard Bedlack","doi":"10.1080/21678421.2024.2346825","DOIUrl":null,"url":null,"abstract":"Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ALSUntangled #75: Portable neuromodulation stimulator therapy.\",\"authors\":\"Laurel Officer, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Michael Benatar, Tulio E. Bertorini, Robert Bowser, Mark B. Bromberg, Andrew Brown, O. Carbunar, Gregory T. Carter, J. Crayle, Keelie Denson, Eva Feldman, Timothy R Fullam, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Danelle Levinson, Xiaoyan Li, Alexandra Linares, Elise Mallon, Javier Mascías Cadavid, C. Mcdermott, Tasnim Mushannen, L. Ostrow, Ronak Patel, Gary L. Pattee, Dylan Ratner, Yuyao Sun, J. Sladky, Paul Wicks, Richard Bedlack\",\"doi\":\"10.1080/21678421.2024.2346825\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2024.2346825\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2346825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在患者兴趣的推动下,ALSUntangled 在此研究了便携式神经调控刺激器 (PoNS™) 在治疗肌萎缩侧索硬化症 (ALS) 方面的潜力。PoNS™ 设备经 FDA 批准用于治疗成年多发性硬化症患者的步态障碍,它利用跨语言神经刺激,通过舌头刺激三叉神经和面部神经,旨在诱导神经可塑性变化。虽然 PoNS 治疗改善多发性硬化症、中风和脑外伤患者的步态和平衡的早期数据很有希望,但尚未对 ALS 进行临床前或临床研究。尽管 PoNS 相当安全,但高昂的费用和处方要求将限制 PoNS 的使用。目前,由于缺乏与 ALS 相关的数据,我们无法认可将 PoNS 用作 ALS 的治疗方法。
Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.